Cite
HARVARD Citation
Klinghammer, K. et al. (n.d.). 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT. Immuno-oncology technology. p. . [Online].